Authors

• Daijiro Harada (ORCID: https://orcid.org/0000-0002-5314-2489)
• Koji Yamazaki (ORCID: https://orcid.org/0000-0003-2025-6268)
• Yoshihiko Taniguchi (ORCID: https://orcid.org/0000-0001-6387-3683)
• Akihiro Tamiya (ORCID: https://orcid.org/0000-0003-3599-2583)
• Hidetoshi Yanai
• Keiichi Nakamura
• Atsuhisa Tamura (ORCID: https://orcid.org/0000-0001-8648-2191)
• Yasuyuki Mizumori (ORCID: https://orcid.org/0000-0002-4134-2600)
• Katsumi Nakatomi
• Yasuhiro Koh (ORCID: https://orcid.org/0000-0002-8758-8980)
• Tomohito Kuwako
• Masahiko Ando (ORCID: https://orcid.org/0000-0003-2891-5424)
• Tsutomu Shinohara (ORCID: https://orcid.org/0000-0002-1562-2043)
• Masahide Oki (ORCID: https://orcid.org/0000-0001-6302-4534)
• Mitsuo Osuga
• Masahide Mori (ORCID: https://orcid.org/0009-0007-9223-3854)
• Shun‐ichi Isa

Institutions

• Wakayama Medical University (JP)
• National Kyushu Medical Center (JP)
• National Hospital Organization Kochi National Hospital (JP)
• Nagoya University Hospital (JP)
• National Hospital Organization Mito Medical Center (JP)
• Toneyama National Hospital (JP)
• Himeji Medical Center (JP)
• National Hospital Organization (JP)
• Shikoku Cancer Center (JP)
• Ureshino Medical Center (JP)
• Nagoya Medical Center (JP)
• Tokyo National Hospital (JP)
• NHO Kinki Chuo Chest Medical Center (JP)

Publication Details

Journal

Cancer Medicine

Published

2025-04-01

DOI

https://doi.org/10.1002/cam4.70861

Citations

1

Primary Topic

Lung Cancer Treatments and Mutations

Type

article

Field-Weighted Citation Impact

1.52

Funders

• Amgen
• Bristol-Myers Squibb
• Eli Lilly and Company
• Pfizer
• AstraZeneca
• GlaxoSmithKline
• Sanofi
• Taiho Pharmaceutical
• BeiGene
• Merit Medical Systems
• Daiichi-Sankyo
• Shionogi
• Ono Pharmaceutical
• Novartis Pharma
• Chugai Pharmaceutical
• FUJIFILM Toyama Chemical
• Daiichi Sankyo Europe